Irina N. Subortseva

Moscow, MOW 125367, Russian Federation

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Red Blood Cell Morphodynamics in Patients with Polycythemia Vera and Stroke.

Red Blood Cell Morphodynamics in Patients with Polycythemia Vera and Stroke.

Journal: International journal of molecular sciences

Published: January 26, 2022

Repeated haploidentical allogeneic hematopoietic stem cell transplantation with TCR αβ/CD19 depletion in patient with primary myelofibrosis. Case report

Repeated haploidentical allogeneic hematopoietic stem cell transplantation with TCR αβ/CD19 depletion in patient with primary myelofibrosis. Case report

Journal: Terapevticheskii arkhiv

Published: July 20, 2021

Thrombosis in patients with myeloproliferative neoplasms. Case report

Thrombosis in patients with myeloproliferative neoplasms. Case report

Journal: Terapevticheskii arkhiv

Published: July 20, 2021

Low JAK2 V617F Allele Burden in Ph-Negative Chronic Myeloproliferative Neoplasms Is Associated with Additional CALR or MPL Gene Mutations.

Low JAK2 V617F Allele Burden in Ph-Negative Chronic Myeloproliferative Neoplasms Is Associated with Additional CALR or MPL Gene Mutations.

Journal: Genes

Published: February 19, 2021

The prognostic value of ASXL1 mutation in primary myelofibrosis. Literature review and clinical case description

The prognostic value of ASXL1 mutation in primary myelofibrosis. Literature review and clinical case description

Journal: Terapevticheskii arkhiv

Published: August 26, 2020

Clinical features and diagnosis of Ph - negative myeloproliferative neoplasms occurring in conjunction with the antiphospholipid syndrome

Clinical features and diagnosis of Ph - negative myeloproliferative neoplasms occurring in conjunction with the antiphospholipid syndrome

Journal: Terapevticheskii arkhiv

Published: April 16, 2020

Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.

Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.

Journal: Terapevticheskii arkhiv

Published: February 01, 2019

Acute ischemic stroke in the setting of essential thrombocytemia (clinical cases).

Acute ischemic stroke in the setting of essential thrombocytemia (clinical cases).

Journal: Terapevticheskii arkhiv

Published: February 01, 2019

Clinical features of essential thrombocythemia and primary myelofibrosis, depending on the molecular characteristics of disease

Clinical features of essential thrombocythemia and primary myelofibrosis, depending on the molecular characteristics of disease

Journal: Terapevticheskii arkhiv

Published: August 03, 2017

Diagnosis of latent polycythemia vera: A clinician's opinion

Diagnosis of latent polycythemia vera: A clinician's opinion

Journal: Terapevticheskii arkhiv

Published: July 27, 2016

Clinical Characteristics of Cerebrovascular Pathology with Patients Suffering from Ph-Negative Myeloproliferative Disease.

Clinical Characteristics of Cerebrovascular Pathology with Patients Suffering from Ph-Negative Myeloproliferative Disease.

Journal: Cerebrovascular diseases extra

Published: May 04, 2016

Experience in treating portal thromboses in patients with chronic myeloproliferative diseases

Experience in treating portal thromboses in patients with chronic myeloproliferative diseases

Journal: Terapevticheskii arkhiv

Published: March 16, 2016

Showing 1-12 of 15

Last Updated: 09/26/2026